GSK News and Press, GlaxoSmithKline PLC From 02/24/26

2026-02-24 12:06:38 ET More on Pfizer, Merck, etc. Merck: Why Investors Should Remain Bullish Despite Patent Risks Pfizer: A Risky 6.3% Yield For Income-Oriented Investors Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) ...

2026-02-24 08:51:38 ET More on GSK GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) GSK plc 2025 Q4 - Results - Earnings Call Presentation GSK plc (GSK) Q4 2025 Earnings Call Transcript CDC said to delay vaccine panel meeting after lawsuit...

2026-02-23 22:35:52 ET Company Background Electromed ( ELMD ) is a small medical device company based in Minnesota. It was founded in 1992 by Robert D. Hansen and Craig N. Hansen, and it IPO’d in 2010 at $4 a share. Shareholders did pretty poorly in the first 9 years ...

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas Bora Pharmaceuticals Co., Ltd. (“Bora”; TWSE: 6472; OTCQX: BORAY), a global leade...

2026-02-22 08:00:00 ET In my last article, "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge" , I have been talking mainly about Merck's (MRK) Q3 results and the efficacy of Keytruda+Pfizer’s (PFE) Padcev in the KEYNOTE-905.... Read the full article on ...

2026-02-20 15:21:00 ET More on pharmaceutical companies Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Pfizer: Recovery Isn't Over, Battered Valuation St...

2026-02-20 14:24:17 ET Shares of Gilead Sciences, Inc. ( GILD ), my favorite in the HIV drugs market, have risen 23.3% since my previous article , " Gilead Sciences: From All-Time Highs To Higher Highs. "... Read the full article on Seeking Alpha For further deta...

2026-02-19 14:10:21 ET More on Pfizer, Sanofi, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) China drug lic...

2026-02-19 13:31:04 ET More on AbbVie, AstraZeneca PLC, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable AbbVie: Dominating Immunology While Building Oncology Upside Merck posts n...

2026-02-18 20:05:00 ET The following segment was excerpted from the Alger International Opportunities Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Alger International Opportunities Fund Q4 2...